March 2, 2021 -- WuXi AppTec has completed the acquisition of Oxgene, a U.K.-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition will allow WuXi to provide its customers with end-to-end support in the creation and development of cell and gene therapies (CGT), according to the company.
Oxgene will become a fully owned subsidiary of WuXi Advanced Therapies, the company's cell and gene therapy contract testing, development, and manufacturing organization business unit. Oxgene will retain its name and become WuXi Advanced Therapies' first facility in Europe.
In addition to providing contract research solutions, Oxgene also provides scalable manufacturing systems that simplify cell and gene manufacturing while reducing costs of production. These technologies include its novel tetracycline enabled self-silencing adenovirus (TESSA) technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing.
Copyright © 2021 scienceboard.net